Levomepromazine Maleate Morningside Healthcare (Levomepromazine Maleate)

The drug blocks dopamine D2 receptors, which reduces psychotic signaling in the brain. It also antagonises histamine H1, muscarinic, adrenergic and serotonergic receptors, contributing to its sedative, antiemetic, and anticholinergic effects. This multi‑receptor activity underlies both its antipsychotic and anti‑nausea actions.

Dosing of Levomepromazine Maleate is individualized. The prescribing clinician determines the appropriate dose based on the patient’s condition, severity, age, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber sets the regimen.

Safety data for Levomepromazine Maleate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should assess each case carefully and discuss alternatives when possible.

To request Levomepromazine Maleate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Compared with newer atypical antipsychotics, Levomepromazine Maleate has a broader receptor profile, offering strong sedation and antiemetic properties. However, it may carry a higher risk of anticholinergic effects, hypotension and extrapyramidal symptoms. Choice of therapy depends on the clinical scenario, patient tolerance and therapeutic goals.

Levomepromazine Maleate should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

The medication is supplied as an oral formulation and is taken by mouth. It may be given with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe cardiac arrhythmias, profound hypotension, seizures, and irreversible movement disorders such as tardive dyskinesia. Immediate medical attention is required if any of these severe reactions are suspected.

Levomepromazine Maleate is contraindicated in patients with known hypersensitivity to phenothiazines, those with severe cardiovascular disease prone to arrhythmias, and individuals with a history of neuroleptic malignant syndrome. Caution is also advised for patients with significant hepatic or renal impairment.